Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
Science, 2020
Arunachalam P., Wimmers F., Mok C., Perera R., Scott M., Hagan T., Sigal N., Feng Y., Bristow L., Tak-Yin Tsang O., Wagh D., Coller J., Pellegrini K., Kazmin D., Alaaeddine G., Leung W., Chan J., Chik T., Choi C., Huerta C., Paine McCullough M., Lv H., Anderson E., Edupuganti S., Upadhyay A., Bosinger S., Maecker H., Khatri P., Rouphael N., Peiris M., Pulendran B.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Infectious Diseases | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathew et al. present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalam et al. report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions.
Science , this issue p. eabc8511 , p. 1210